Strengths

A current ratio of 2.84 and quick ratio of 1.67 indicate adequate near-term liquidity, which is stronger than many leveraged medtech peers facing tighter working-capital buffers.

The company’s leverage remains manageable at 1.43x net debt to EBITDA and 0.55x debt-to-equity, supporting financial flexibility relative to more highly levered competitors.

Despite negative TTM ROIC of -3.5%, the balance-sheet cushion can preserve operating continuity, whereas weaker peers may be forced into more dilutive financing.

A large cash conversion cycle of 233.7 days reflects working-capital strain, but the liquidity profile partially offsets this pressure versus peers with thinner cash reserves.

Weaknesses

Negative TTM ROIC of -3.5% shows capital is not earning its cost, which is structurally weaker than profitable peers with positive reinvestment returns.

A cash conversion cycle of 233.7 days ties up cash for extended periods, reducing operating efficiency versus peers with faster inventory and receivables turnover.

Leverage at 1.43x net debt to EBITDA limits strategic flexibility, because debt service competes with investment needs more than in net-cash competitors.

The absence of disclosed margin metrics in the provided data leaves profitability visibility limited, which can weigh on peer-relative valuation and operating confidence.

Opportunities

Reducing the 233.7-day cash conversion cycle would release working capital, improving cash generation more directly than peers with already efficient cycles.

If management converts liquidity into higher-return product and commercial investments, ROIC could improve from negative territory toward peer norms.

Moderate leverage leaves room to refinance or optimize capital structure, which could lower financing drag relative to more indebted competitors.

Operational execution that shortens receivables and inventory days would strengthen resilience, because peers with leaner working capital typically convert sales into cash faster.

Threats

Persistent negative ROIC raises the risk of value destruction, especially if peers sustain positive returns while OFIX continues to reinvest below cost of capital.

The 233.7-day cash conversion cycle increases exposure to demand shocks and supply-chain disruptions, because cash remains tied up longer than in faster-turning peers.

If leverage rises before profitability improves, refinancing risk could intensify versus peers with stronger earnings coverage and lower debt dependence.

Competitive pressure from more efficient medtech peers can compress pricing and delay cash recovery, making working-capital inefficiency harder to absorb.

Overall Score

OFIX shows a mixed peer position, with acceptable liquidity and moderate leverage offset by negative returns on capital and a very long cash conversion cycle.